Shares, 52-Week Range, Recent Trend
Quest Diagnostics Inc. (NYSE: DGX) shares rose sharply following its Q4 and FY 2025 earnings release. The stock surged 6.56% intraday to $203.80, after touching a session high of $205.72. The move pushed the stock close to its 52-week peak. Quest Diagnostics trades within a 52-week range of $157.20 to $205.72. Shares have trended upward in recent sessions, supported by earnings momentum and investor interest in diagnostic testing volumes. The stock recently traded near record levels and remains above its 52-week average price band. Outstanding shares stand at roughly 111 million.
Q4 2025 Results
Quest Diagnostics reported fourth-quarter 2025 revenue of $2.81 billion, up 7.1% year over year. Reported diluted EPS rose to $2.18, increasing 11.8% YoY, while adjusted diluted EPS reached $2.42, up 8.5% YoY. Growth was driven by demand for diagnostic testing, strategic collaborations, and contributions from prior acquisitions, according to the company’s press materials.
Margins, Volumes, Billings Context
Profit expansion outpaced revenue growth in the quarter, reflecting operating leverage and productivity initiatives. The company also cited testing volume expansion and advanced diagnostics mix as supportive factors in presentation commentary.
Full-Year 2025 Performance
For full-year 2025, revenue climbed to $11.04 billion, marking 11.8% growth from 2024. Reported diluted EPS increased to $8.75, up 13.8% YoY, while adjusted diluted EPS rose 10.3% to $9.85. Operating cash flow totaled $1.89 billion for the year. Management highlighted double-digit annual growth in both revenue and earnings, supported by acquisitions, partnerships with health systems, and expanded service capabilities.
Strategic and Operating Highlights
During 2025, Quest:
- Advanced large health-system collaborations, including joint-venture lab initiatives.
- Expanded dialysis-center testing services.
- Integrated prior acquisitions to drive geographic growth.
- Formed technology partnerships to modernize order-to-cash systems.
2026 Guidance
For full-year 2026, Quest Diagnostics expects:
- Revenue: $11.70B – $11.82B
- Reported EPS: $9.45 – $9.65
- Adjusted EPS: $10.50 – $10.70
The outlook signals continued top- and bottom-line expansion.
Analyst Actions
No analyst upgrades, downgrades, or price-target revisions were disclosed in company materials released alongside the results.